Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 3 1Phase 2 1

Status

Unknown 1Recruiting 1Completed 1

Sponsor Class

OTHER 2OTHER_GOV 1

Study Type

Interventional 3Observational 1

Sponsor

Cancer Type

NET 3Endocrine 3Gastrointestinal 1

Conditions

Neuroendocrine Tumors 3Gastro-enteropancreatic neuroendocrine tumor 3Pheochromocytoma 1Paraganglioma 1Metastatic Neuroendocrine Prostate Cancer 1Carcinoma, Neuroendocrine 1

Interventions

lutetium Lu 177 dotatate 34Everolimus 33lanreotide 13gallium Ga 68 dotatate 13Temozolomide 13Magnetic Resonance Spectroscopy 13Nivolumab 12pembrolizumab 11Octreotide 11Capecitabine 11177Lu-octreotide, DOTA(0)-Tyr(3)- 10cabozantinib 9Positron Emission Tomography Computed Tomography 93-Iodobenzylguanidine 9surufatinib 8Sunitinib 8Specimen Handling 7Carboplatin 7pasireotide 6amino-acid, glucose, and electrolyte solution 690Y-octreotide, DOTA-Tyr(3)- 6lenvatinib 5Lutetium-177 5Ipilimumab 5Fluorodeoxyglucose F18 5Etoposide 5Cisplatin 5Bevacizumab 5telotristat ethyl 4olaparib 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Interventional × Neuroendocrine Tumors × copper dotatate CU-64 × Clear all
NCT06878664 2025-09-02

RIALTO

Grupo Espanol de Tumores Neuroendocrinos

Phase 3 Recruiting
166 enrolled
EndocrineNET

Neuroendocrine Tumors

NCT05709171 2023-11-22

Dual 64Cu-DOTATATE and 18F-FDG PET/CT Imaging of Patients With Neuroendocrine Neoplasms

Rigshospitalet, Denmark

Phase 2 Unknown
200 enrolled
EndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor, Carcinoma, Neuroendocrine, Neuroendocrine Tumors

NCT02125474 2019-11-14

Efficacy of 177-Lu-DOTA 0, Tyr 3 Octreotate

Instituto Nacional de Cancerologia, Columbia

Phase NA Completed
39 enrolled
EndocrineNET

Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡